{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:38:03Z","timestamp":1787060283874,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006599","name":"Focused Ultrasound Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.neuropharm.2019.107827","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:35:55Z","timestamp":1571776555000},"page":"107827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Affinity-matured \u2018aquaporumab\u2019 anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"162","author":[{"given":"Tianjiao","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukmanee","family":"Tradtrantip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay-Wah","family":"Phuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-2202","authenticated-orcid":false,"given":"Alan S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107827_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/bpa.12098","article-title":"Experimental models of neuromyelitis optica","volume":"24","author":"Bradl","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib3","doi-asserted-by":"crossref","unstructured":"Bruscolini, A., Sacchetti, M., La Cava, M., Gharbiya, M., Ralli, M., Lambiase, A., De Virgilio, A., Greco, A. Diagnosis and management of neuromyelitis optica spectrum disorders \u2013 an update. Autoimmun. Rev. 17, 195-200.","DOI":"10.1016\/j.autrev.2018.01.001"},{"key":"10.1016\/j.neuropharm.2019.107827_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2019.107827_bib5","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.107827_bib6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","article-title":"Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica","volume":"15","author":"Duan","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2019.107827_bib7","article-title":"Experimental animal models of aquaporin-4-IgG seropositive neuromyelitis spectrum disorders: progress and shortcomings","author":"Duan","year":"2019","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-2094-5-22","article-title":"Neuromyelitis optica pathogenesis and aquaporin 4","volume":"5","author":"Graber","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2019.107827_bib9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamaneurol.2014.775","article-title":"Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum","volume":"71","author":"Guo","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jns.2013.05.035","article-title":"NMO sera down-regulate AQP4 in human astrocyte and induce cytotoxicity independent of complement","volume":"331","author":"Haruki","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107827_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1073\/pnas.1109980108","article-title":"Molecule outcomes of neuromyelitis optic (NMO)-IgG binding to aquaporin-4 in astrocytes","volume":"109","author":"Hinson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2019.107827_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/glia.22635","article-title":"Neuromyelitis optica IgG stimulates an immunological response in rat astrocyte cultures","volume":"62","author":"Howe","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2019.107827_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2019.107827_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuropharm.2019.107827_bib17","first-page":"2327","article-title":"Pharmacokinetics of therapeutic monoclonal antibodies used in oncology","volume":"25","author":"Leveque","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.neuropharm.2019.107827_bib18","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12264-015-1552-6","article-title":"Experimental models of neuromyelitis optica: current status, challenges and future directions","volume":"31","author":"Li","year":"2015","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.neuropharm.2019.107827_bib19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.107827_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of autoantibody-induced pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.neuropharm.2019.107827_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020090","article-title":"Aquaporin-4 water chanel in the brain and its implication for health and disease","volume":"8","author":"Mader","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2019.107827_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/mus.24298","article-title":"Transient hyperCKemia in the setting of neuromyelitis optica","volume":"50","author":"Malik","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neuropharm.2019.107827_bib23","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/awm047","article-title":"Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis","volume":"130","author":"Misu","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2019.107827_bib24","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib25","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib26","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","article-title":"Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays","volume":"287","author":"Phuan","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.107827_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","article-title":"C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica","volume":"125","author":"Phuan","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib28","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","article-title":"Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica","volume":"286","author":"Ratelade","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.107827_bib29","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/glia.22417","article-title":"Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1\/M23 isoform content, or supramolecular assembly","volume":"60","author":"Rossi","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2019.107827_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1083\/jcb.201308118","article-title":"Aggregation state determines the localization and function of M1- and M23-Aquaporin-4 in astrocytes","volume":"204","author":"Smith","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib31","first-page":"383","article-title":"Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica","volume":"130","author":"Soltys","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2019.107827_bib32","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","article-title":"Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase","volume":"83","author":"Tradtrantip","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00401-017-1734-6","article-title":"Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica","volume":"134","author":"Tradtrantip","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib34","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","article-title":"Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica","volume":"26","author":"Tradtrantip","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2019.107827_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107827_bib37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819303934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:59:02Z","timestamp":1758437942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819303934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":36,"alternative-id":["S0028390819303934"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107827","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Affinity-matured \u2018aquaporumab\u2019 anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107827"}}